InvestorsHub Logo
Post# of 252486
Next 10
Followers 6
Posts 703
Boards Moderated 0
Alias Born 09/23/2006

Re: biomaven0 post# 128022

Sunday, 10/09/2011 10:03:30 AM

Sunday, October 09, 2011 10:03:30 AM

Post# of 252486
MNTA: So one reading of this law is that Amphastar (or Teva) could freely infringe on MNTA's patent during the development process just so long as they don't infringe during the manufacturing process.

Don't know if anyone will know, but my response to this is that this begs the question of whether or not Amphastar needs to use the potentially protected molecule characterization process as part of their Quality Assurace in their production of aL. If they can get by with the FDA demonstrating that the manufacture does not need regular checks on production, then Peter's find is a broadside to MNTA's patent claims, IMO.

aj

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.